Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GH Research PLC - Ordinary Shares
(NQ:
GHRS
)
10.60
+0.91 (+9.39%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GH Research PLC - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
January 31, 2025
From
GH Research PLC
Via
GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 22, 2025
Via
Benzinga
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
January 10, 2025
From
GH Research PLC
Via
GlobeNewswire
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024
From
GH Research PLC
Via
GlobeNewswire
3 Fast-Growing Stocks Analysts See Doubling in Price
November 11, 2024
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
Via
MarketBeat
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...
Via
Talk Markets
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
September 05, 2024
Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and...
Via
Benzinga
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 03, 2024
From
GH Research PLC
Via
GlobeNewswire
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
September 03, 2024
From
GH Research PLC
Via
GlobeNewswire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
July 06, 2024
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.
Via
InvestorPlace
Exposures
Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
July 03, 2024
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
Via
InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
June 09, 2024
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 05, 2024
Via
Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
May 03, 2024
GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024
From
GH Research PLC
Via
GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
April 12, 2024
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via
Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
March 30, 2024
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via
Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.